[go: up one dir, main page]

MX2016013711A - Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales. - Google Patents

Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.

Info

Publication number
MX2016013711A
MX2016013711A MX2016013711A MX2016013711A MX2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A
Authority
MX
Mexico
Prior art keywords
treatment
mglu2
intellectual disabilities
antagonists
relates
Prior art date
Application number
MX2016013711A
Other languages
English (en)
Inventor
Woltering Thomas
Wichmann Juergen
Saxe Michael
M Ballard Theresa
Gatti Mcarthur Silvia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016013711A publication Critical patent/MX2016013711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención hace referencia a una nueva utilización médica de ciertos compuestos químicos y composiciones farmacológicas que los contienen. La invención hace referencia a compuestos que son moduladores alostéricos negativos de mGlu2/3 para su utilización en el tratamiento de varias discapacidades intelectuales. En otro aspecto, la invención hace referencia a una composición farmacológica para su utilización en el tratamiento de varias discapacidades intelectuales que incluye un compuesto de acuerdo con la invención y un transportador farmacológicarnente aceptable.
MX2016013711A 2014-04-23 2015-04-20 Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales. MX2016013711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14165632 2014-04-23
PCT/EP2015/058466 WO2015162076A2 (en) 2014-04-23 2015-04-20 Mglu2/3 antagonists for the treatment of intellectual disabilities

Publications (1)

Publication Number Publication Date
MX2016013711A true MX2016013711A (es) 2017-01-13

Family

ID=50513799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013711A MX2016013711A (es) 2014-04-23 2015-04-20 Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.

Country Status (12)

Country Link
US (4) US20170035767A1 (es)
EP (1) EP3134089A2 (es)
JP (1) JP2017513844A (es)
KR (1) KR20160143853A (es)
CN (2) CN110483525A (es)
AR (1) AR100151A1 (es)
BR (1) BR112016021727A2 (es)
CA (1) CA2943877A1 (es)
MA (1) MA39901A (es)
MX (1) MX2016013711A (es)
RU (1) RU2016144702A (es)
WO (1) WO2015162076A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357433A1 (en) 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
SI1224174T1 (en) 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
EP1379511B1 (en) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
NZ528345A (en) 2001-04-12 2005-04-29 F Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
DE10330447A1 (de) 2003-07-05 2005-02-10 Daimlerchrysler Ag Vorrichtung und Verfahren zum Vergleich von Bauteilen
ATE374030T1 (de) 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
JP4608542B2 (ja) 2004-06-21 2011-01-12 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリミジン誘導体
BRPI0607927A2 (pt) 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
BRPI0609719B8 (pt) * 2005-03-23 2021-05-25 Hoffmann La Roche derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
EP1934214B1 (en) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
AU2007229552C1 (en) * 2006-03-29 2013-06-13 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mGluR2 antagonists
US8012986B2 (en) 2007-04-02 2011-09-06 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives as MGLUR2 antagonists
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
EP2666775A1 (en) * 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
KR20150070187A (ko) * 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제

Also Published As

Publication number Publication date
RU2016144702A (ru) 2018-05-24
JP2017513844A (ja) 2017-06-01
CA2943877A1 (en) 2015-10-29
CN110483525A (zh) 2019-11-22
KR20160143853A (ko) 2016-12-14
US20180235971A1 (en) 2018-08-23
WO2015162076A2 (en) 2015-10-29
CN106132966A (zh) 2016-11-16
US20250017937A1 (en) 2025-01-16
MA39901A (fr) 2017-03-01
AR100151A1 (es) 2016-09-14
US20170035767A1 (en) 2017-02-09
US20190343839A1 (en) 2019-11-14
WO2015162076A3 (en) 2015-12-10
BR112016021727A2 (pt) 2017-08-15
EP3134089A2 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
MY187540A (en) Compounds active towards bromodomains
PH12015502615B1 (en) Chemical compounds
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
NZ737399A (en) Ccr2 modulators
PH12016501791B1 (en) Muscarinic receptor agonists
MX2015004604A (es) Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
TW201613864A (en) Novel compounds
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX362879B (es) Usos novedosos.
IL264880A (en) Preparations for oral administration of active substances
PH12016500124A1 (en) Via antagonists to treat phase shift sleep disorders
WO2015001541A3 (en) Pharmaceutical film composition
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
MA39901A (fr) Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
PH12017500346A1 (en) Film coated tablet for the treatment of acute pain
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin